Vaxart Q2 revenue falls on lower government contract income
VXRT•Outlook
- Vaxart expects topline efficacy and safety data from its Phase 2b COVID-19 trial in H1 2027
- Company anticipates cash runway into the second quarter of 2027
- Vaxart is exploring business development partnerships and non-dilutive funding to extend cash runway
Overview
- US oral vaccine developer's Q2 revenue fell yr/yr, mainly on lower government contract revenue
- Net loss for Q2 narrowed from prior year, reflecting lower R&D expenses
- Company reported topline safety data from 400-person Phase 2b COVID-19 vaccine trial cohort
Key Details
| Metric | Beat/Miss | Actual | Consensus Estimate |
| Q2 Revenue | $27.19 mln | ||
| Q2 Net Loss | $13.49 mln | $29.78 mln (2 Analysts) | |
| Q2 Operating Income | -$13.17 mln | -$29.95 mln (2 Analysts) | |
| Q2 Pretax Loss | $13.47 mln | $29.78 mln (2 Analysts) | |
| Q2 Loss Per Basic Share | $0.06 | ||
| Q2 Operating Expenses | $40.36 mln |
Result Drivers
Related News
Ellington Financial Q2 adjusted EPS and net income beat estimates on Longbridge strength
EFC•
Oculis Q2 2026 loss narrows on CHF 12.1 million warrant valuation gain, FX swing to profit
OCS•
